Vogenx, a North Carolina biotech, has raised about $81 million in an initial public offering to advance a treatment for a serious but under-recognized complication of weight-loss surgery: dangerous drops in blood sugar.
The company sold 6.25 million shares at $13 each and began trading on the Nasdaq under the ticker VOGX. Founded in 2021 and based in Raleigh, Vogenx is developing mizagliflozin, an oral drug licensed from Japan’s Kissei Pharmaceutical.
The problem it targets
The lead program takes aim at post-bariatric hypoglycemia (PBH) — episodes of dangerously low blood sugar that can develop months or years after weight-loss surgery such as gastric bypass. As bariatric procedures become more common, so does awareness of PBH, which currently has no FDA-approved treatment.
How the drug works
Mizagliflozin is an SGLT1 inhibitor designed to slow the absorption of glucose in the gut, blunting the rapid blood-sugar swings that trigger hypoglycemic episodes. It is taken orally, three times a day. Vogenx has said it expects results from a Phase 2b trial around 2027.
Why it matters
The IPO is a modest but notable raise in a cautious biotech market, and it spotlights a niche where the rise of GLP-1 drugs and weight-loss surgery is creating new, downstream medical needs. The drug remains investigational, and its commercial prospects hinge on trial data still years away.